Biotechnology, genomics, vaccines & health technology

The Molecular Toolkit a Candidate Must Command

Biotechnology questions in UPSC reward conceptual clarity over jargon. Begin with the central dogma: DNA is transcribed to mRNA, which is translated into protein. Modern biotech intervenes at each stage.

Recombinant DNA technology (Cohen and Boyer, 1973) inserts a gene from one organism into another using restriction enzymes and ligases, producing transgenic organisms. India's first transgenic crop, Bt cotton, was approved by the Genetic Engineering Appraisal Committee (GEAC) in 2002; Bt brinjal received GEAC clearance in 2009 but was placed under an indefinite moratorium by the Environment Ministry in February 2010. GM mustard (DMH-11) received environmental release approval from GEAC in October 2022, currently sub judice in the Supreme Court.

Gene editing is the high-yield frontier. CRISPR-Cas9, developed by Jennifer Doudna and Emmanuelle Charpentier (Nobel Chemistry, 2020), acts as molecular scissors guided by a single-guide RNA. In November 2023 the UK's MHRA approved Casgevy (exagamglogene autotemcel), the world's first CRISPR therapy, for sickle-cell disease and beta-thalassaemia; the US FDA followed in December 2023. India's Department of Biotechnology issued the 2022 guidelines exempting SDN-1 and SDN-2 genome-edited plants (those with no foreign DNA) from the stricter rules applicable to GMOs under the Environment (Protection) Act, 1986 — a fact frequently misstated in answers.

Genomics and Personalised Medicine

The Human Genome Project (declared complete in 2003) mapped the roughly 3.2 billion base pairs of human DNA. India's flagship is the Genome India Project, coordinated by the Department of Biotechnology, which announced in January 2024 that it had sequenced 10,000 healthy Indian genomes across 99 population groups, building a reference database for a population marked by extraordinary genetic diversity and high consanguinity.

Distinguish two terms examiners conflate: gene therapy corrects a defective gene in a patient (somatic edits are non-heritable; germline editing is prohibited), while genomics is the study of entire genomes. Pharmacogenomics tailors drug choice to genetic profile.

Vaccine Platforms

UPSC tests vaccine technology through current affairs. Memorise the platform taxonomy:

• Inactivated/whole-virion: Covaxin (BBV152), developed by Bharat Biotech with ICMR-NIV, granted restricted emergency use in January 2021 and WHO Emergency Use Listing in November 2021.
• Viral vector: Covishield (Oxford-AstraZeneca, made by Serum Institute); Sputnik V.
• mRNA: Pfizer-BioNTech and Moderna; India's first indigenous mRNA vaccine, Gemcovac, by Gennova Biopharmaceuticals, received emergency approval in June 2022.
• Protein subunit: Corbevax (Biological E), India's first indigenously developed RBD protein subunit vaccine, approved December 2021.
• DNA: ZyCoV-D by Zydus Cadila — the world's first approved DNA vaccine for humans (August 2021), needle-free.

Note mRNA platform advantages: rapid design, no live pathogen, scalable; disadvantages: cold-chain requirements (ultra-low temperature for first-generation formulations).

Why This Matters for the Exam

Biotechnology and health technology serve Prelims GS (science and technology developments) and Mains GS-3, which explicitly lists "awareness in the fields of IT, space, computers, robotics, nano-technology, bio-technology" and "issues relating to intellectual property rights." It also bleeds into GS-2 (health, governance) and GS-4 (bioethics).

How It Is Tested

Prelims questions are factual and discriminating. PYQs include 2023's question on CRISPR-Cas9 (asking what it is used for — gene editing, not cancer vaccine production), the 2021 question on mRNA vaccines (what distinguishes them: they carry molecular instructions to make a protein, not the weakened pathogen), and recurring items on Bt crops, gene drives and DNA fingerprinting. The examiner loves the platform-mismatch trap: pairing a vaccine with the wrong technology. Drill the table in the previous block until it is automatic.

Mains demands analytical balance. A GM-crops question requires you to weigh yield and pest resistance against biodiversity, the Cartagena Protocol on Biosafety (2003), farmer dependence and the GEAC regulatory process. Cite the Biological Diversity Act, 2002 and its 2023 amendment, the National Biopharma Mission (i3 programme), and the BioE3 Policy (Biotechnology for Economy, Environment and Employment), approved by the Union Cabinet in August 2024, which targets high-performance biomanufacturing.

High-Yield Retention Set

Lock down these authorities and dates:

• GEAC under the Environment (Protection) Act, 1986 — apex regulator for GMOs.
• The proposed Biotechnology Regulatory Authority of India (BRAI) Bill — lapsed; know that India still lacks a single statutory biotech regulator.
• Cartagena Protocol (2000, in force 2003) and Nagoya Protocol (2014) on access and benefit-sharing.
• TRIPS Article 27.3(b) and India's Patents Act Section 3(d) (anti-evergreening), upheld in Novartis v. Union of India (2013).
• Mission COVID Suraksha and National One Health Mission (2023).
• Ayushman Bharat Digital Mission (2021) and the CoWIN platform as health-tech governance.

In the answer booklet, structure GS-3 biotech answers as: what the technology is (one line), its application, the regulatory and ethical frame, and a forward statement linking to a scheme. This converts a recall question into a 7-mark structured response. Never write a vaccine answer without naming at least one Indian indigenous product and its developer.